Correction to: Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer (Targeted Oncology, (2020), 15, 2, (163-174), 10.1007/s11523-020-00714-0)

Ramesh K. Ramanathan, Daniel D. Von Hoff, Ferry Eskens, George Blumenschein, Donald Richards, Isabelle Genvresse, Susanne Reschke, Camille Granvil, Adam Skubala, Carol Peña, Klaus Mross

Research output: Contribution to journalComment/debatepeer-review

Abstract

The article Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer.

Original languageEnglish (US)
Pages (from-to)803
Number of pages1
JournalTargeted Oncology
Volume15
Issue number6
DOIs
StatePublished - Dec 2020

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Correction to: Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer (Targeted Oncology, (2020), 15, 2, (163-174), 10.1007/s11523-020-00714-0)'. Together they form a unique fingerprint.

Cite this